Reasonable pricing clauses are needed to ensure that American taxpayers receive a fairer return on their investment for essential therapies.
The Biden Administration could take a number of legal measures to ensure the timely entrance of a generic competitor to Xtandi.
As the NIH prepares for a massive influx of funding, it must follow through on its commitment to address health research funding disparities.
It remains to be seen whether Congress or the Administration adopt more decisive measures toward the control of drug prices than they have in the past.
The pandemic makes a stronger case for the need to explicitly incorporate into our legal system a right to repair and supply products in emergencies.
By James Love This is a story about U.S. patent number 6,958,335, and how it took more than 18 years for Novartis to acknowledge National Institutes of Health (NIH) funding in a key patent for Gleevec, allowing Novartis to shape the narrative regarding its role in the development of Gleevec, and also to avoid demands…
By Suzanne M. Rivera, Ph.D. Much attention has been paid to the government shutdown that started last week. Many of us heard heart-tugging stories on public radio about the NIH closing down new subject enrollment at its “House of Hope,” the clinical trial hospital on the NIH main campus. These stories gave many people the…
By Scott Burris Here’s where some in Congress would like us to go: ScienceInsider reports: The new chair of the House of Representatives science committee has drafted a bill that, in effect, would replace peer review at the National Science Foundation (NSF) with a set of funding criteria chosen by Congress. For good measure, it…
By Scott Burris Nothing threatens a know-nothing more than the prospect of someone knowing something. Hence there has been increasing pressure on and from some in Congress to reduce government funding of social science research. I hope every reader of this blog is aware that an appropriations rider added by Tom Coburn has drastically restricted…
By Dov Fox We’re not talking vasectomies or condoms. Medical Daily reports that the NIH has awarded a $4.7 million grant to come up with a “Pill” for men. Most previous attempts to develop such contraceptives used testosterone to reduce the number of sperm men produce. This one takes aim at its mobility instead, using a non-hormonal compound that…
